Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …

History shows that metal-based drugs and remedies have been known and used since very
ancient times. For example, silver was employed in the treatment of wounds and ulcers …

The clinical success of the platinum-based chemotherapeutic agents has prompted the
investigation of coordination and organometallic complexes of alternative metal centers for …

The small molecule anticancer agent cisplatin and its Pt (II) analogs carboplatin and
oxaliplatin are widely used to treat a variety of tumorigenic diseases. Despite their structural …

Interest in the medicinal properties of ruthenium (II)–arene compounds has grown rapidly
over the last decade. In this account we describe the origins of the field and subsequently …

Highlights•Osmium complexes are promising anticancer agents.•In vitro assays revealed
antiproliferative activity in nanomolar concentrations.•New leads of osmium are well …

8-Hydroxyquinoline and its derivatives have a broad variety of pharmacological properties,
which make them an ideal bioactive building block in the development of metal-based …

Metallodrugs have a central role in the treatment and diagnosis of diseases. To overcome
potential toxicity and equip metal-based anticancer agents with biological activity, the choice …

A series of novel C, N-cyclometalated benzimidazole ruthenium (II) and iridium (III)
complexes of the types [(η6-p-cymene) RuCl (κ2-N, CL)] and [(η5-C5Me5) IrCl (κ2-N …

Organometallic metal (arene) anticancer agents require ligand exchange for their anticancer
activity and this is generally believed to confer low selectivity for potential cellular targets …